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Abstract
Physicians treating HIV infection concentrate not only on the viral
management but they also have to take into account the potential age
and lifestyle-related conditions likely to influence long-term morbidity,
correlated with patients’ survival. Hypertension, diabetes,
cardiovascular, bone, kidney and liver disease, better than opportunistic
infection, depict the changing spectrum of HIV disease in the HAART era.
These conditions, the so called non infectious co-morbidities, are age-
related diseases affecting the general population. However, their
prevalence in HIV-infected individuals is higher, with earlier onset,
probably as a result of the complex inter-relationship between HIV
infection, co-infection and antiretroviral therapy.
Regular screening for non infectious co-morbidities helps identify those
asymptomatic HIV-infected individuals who are most at risk of
developing comorbidities; this means that appropriate intervention,
either by lifestyle changes to reduce modifiable risk factors or by the use
of pharmacological management, can be initiated.
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Expert opinion 
 
Some of the first reports of lipodystrophy in HIV-infected patients receiving
protease inhibitors (PIs) date back to 1998, when they raised questions about
antiretroviral therapy (ART), which had just become available at that
time.1Lipodystrophy could be described as one or both (mixed forms) of the
following: peripheral fat loss (lipoatrophy), central fat accumulation
(lipohypertrophy), usually, but not invariably, associated with alterations of lipid
metabolism and impairment of insulin sensitivity possibly leading to diabetes
mellitus.2
Thymidine analogue use was considered to be the leading risk factor for
lipoatrophy development.3 In the context of earlier detection of HIV infection and
newly available drugs and drug classes that replace regimens with thymidine
analogue-based backbones or ritonavir boosting of protease inhibitors,4it is
reasonable to foresee a decrease in the prevalence of lipodystrophy in the coming
years.2
Lipodystrophy includes manifestations which often overlap with the diagnosis
criteria for metabolic syndrome, leading to increased risk of cardiovascular
disease (CVD) and diabetes in the general population. It is extremely important
for physicians treating HIV infection to concentrate not only on the viral
management but to also take into account the potential age and lifestyle-related
conditions likely to influence long-term morbidity, correlated with patients’
survival. Hypertension, diabetes, cardiovascular, bone, kidney and liver disease,
better than opportunistic infection, depict the changing spectrum of HIV disease
in the HAART era.
These conditions, the so called non infectious co-morbidities, are age-related
diseases affecting the general population. However, their prevalence in HIV-
infected individuals is higher, with earlier onset, probably as a result of the
complex inter-relationship between HIV infection, co-infection and ART.5,6
European AIDS clinical society (EACS) guidelines were the first to suggest a
regular screening for non infectious co-morbidities in the context of the
management of antiretroviral drugs.
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Regular screening helps identify those asymptomatic HIV-infected individuals who
are most at risk of developing comorbidities; this means that appropriate
intervention, either by lifestyle changes to reduce modifiable risk factors or by the
use of pharmacological management, can be initiated. Although currently some of
the assessment criteria are identical to those applied in the general population,
for example, using the Framingham score for calculation of CVD risk, caution is
required as some of these generalized assessment tools do not allow for the
additional potential risk caused by HIV-related inflammatory processes. What
makes risk prediction difficult in HIV-infected individuals, is the presence of
additional potentially contributing factors besides the traditional ones: HIV-
associated immunodeficiency and immune activation, chronic inflammation as
well as drug toxicities.
Risk prediction algorithms appear to underestimate events in the context of HIV
in a yet relatively young population. As such, clinicians are increasingly interested
in identifying those patients which qualify for primary prevention rather than
identifying those who are theoretically at risk.2
Therefore, risk prediction cannot be considered a diagnostic process per se, but
rather the way to stratify and subsequently identify patients who need further
evaluation in a multidisciplinary approach. Patients identified in the intermediate
risk groups should be evaluated for subclinical organ diseases.
To provide a few examples, with regards to cardiovascular diseases as patterns of
subclinical organ disease, coronary calcium scoring or carotid intima-media
thickness measurement can be mentioned as markers of global atherosclerosis
burden and flow-mediated dilation testing or pulse wave velocity as markers of
endothelial dysfunction.
In regard to bone diseases examples of subclinical organ disease, useful tools
include DEXA and X-ray morphometric assessment of vertebral body.
An ageing HIV population demands a new approach to the management of HIV
infection. It requires HIV physicians to be vigilant for the presence of
comorbidities, preferably via initial screening and regular monitoring, to allow
appropriate referral to other clinical specialists when required, for example,
endocrinologists, cardiovascular specialists, renal physicians and hepatologists. In
addition, tracking of disease progression and adjustments to management
protocols need to be considered as part of multidisciplinary care that
accommodates the increasing number of factors influencing non-HIV-related
outcomes.
Educating physicians is essential, potentially through existing programmes for
providing physicians with the extensive knowledge required in order to effectively
diagnose and treat age-associated, HIV-related comorbidities.
Some web based tools may facilitate this work from the bench to the bed side.
Among them is MyHIVClinic (www.myhivclinic.com/). This is an educational
resource designed as a ‘virtual treatment clinic’ to support healthcare
professionals in the management of the most common co-morbidities
experienced by people living and ageing with HIV.
The website has been optimized for use on mobile phones and tablet devices.
Users can simply navigate through different departments of the virtual clinic
according to their educational needs and interests and quickly find the
information, tools and educational resource that they need, including:
• Educational material on the most common co-morbidities experienced by people
living and ageing with HIV
• Summaries of the key considerations when managing a number of comorbid
conditions in the context of HIV infection, including current options and
implications for assessment, management and care
• Access to relevant current guidelines, tools, reference lists and patient case
studies for commonly occurring co-morbidities
Registered users can set their preferences and subscribe to the new information
and content update alerts that are of most interest to them. The following
departments are currently open on myHIVclinic: HIV >50 years, Cardiology and
Endocrinology. Currently these departments cover: prevention of cardiovascular
disease, coronary artery disease, dyslipidemia, hypertension, thromboembolic
disease, diabetes, osteoporosis, thyroid disease, cognitive impairment, renal
impairment, aspects of ageing (including frailty).
A practical example of this integrated multidisciplinary approach is the Metabolic
Clinic of Modena University in Italy, a tertiary level referral centre for diagnosis
and treatment of metabolic and morphologic alteration in HIV people.
HIV patients attending the Metabolic Clinic are evaluated by a multidisciplinary
team consultant service consisting of infectious diseases physicians, nutritionists,
personal trainers for physical activities, psychologists, cardiologist, nephrologists,
endocrinologists and plastic surgeons, in the efforts to provide a holistic approach
to the changed health needs of people living with HIV.
Given the fact HIV infection is increasingly regarded as a chronic condition, it is
important for the patients to benefit from the care of a multi-disciplinary team,
particularly in the context of a population aging with HIV and respectively aging
on ART. All aspects regarding non infectious co-morbidities need to be taken into
account in order to be able to choose the optimal ARV regimen for each patient.
There is still work underway but nowadays, we find ourselves closer to reaching
the goal of individualized care in HIV infection.
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